Panacea Biotec Limited (PANACEABIO) AI Stock Analysis

• Market Cap: ₹21.73B
• Dividend Yield: N/A
• Average Volume (3M): 12.44K
• Price to Earnings (P/E): 144.8
• Beta (1Y): 1.72
• Revenue Growth: 9.78%
• EPS Growth: 50.78%
• Country: IN
• Employees: 1,936
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): 0.65
• Shares Outstanding: 61,250,744
• 10 Day Avg. Volume: 14,140
• 30 Day Avg. Volume: 12,438
• PEG Ratio: -0.53
• Price to Book (P/B): 3.31
• Price to Sales (P/S): 4.94
• P/FCF Ratio: -35.56
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 51 Neutral
• Price Target: ₹336.00 ▼(-6.28% Downside)
• Action: Reiterated Date: 01/09/26
• Date: Action: Reiterated 01/09/26

The score is primarily constrained by weak financial performance (ongoing losses, stagnant revenue, and negative operating/free cash flow). Technicals are a positive offset with an uptrend and bullish momentum, but valuation remains pressured due to a large negative P/E and no dividend yield data.

Positive Factors

Low leverage / strong equity ratio

A very low debt-to-equity ratio and a ~64.7% equity ratio provide durable financial flexibility. This reduces refinancing/default risk, supports funding of operations or R&D from equity, and gives management room to weather cyclical pharma demand or invest in vaccine capacity without heavy leverage.

High gross profit margin

A gross margin near 64% signals structural cost advantage or pricing power on core products. This margin cushion supports long-term profitability if SG&A and R&D are controlled, enabling reinvestment in biologics/vaccines and insulating the business from input cost swings over months to years.

Vertical integration and manufacturing capability

Owning R&D, manufacturing and distribution creates durable competitive advantages: faster scale-up for vaccines, tighter quality control, capture of manufacturing margins, and ability to offer contract manufacturing. This integration supports sustainable revenue channels and institutional tender access.

Negative Factors

Negative operating and free cash flow

Persistent negative operating and free cash flow indicate the core business is not self-funding. Over 2-6 months this erodes liquidity, forces reliance on financing or equity, constrains capex/R&D for vaccine programmes, and raises execution risk for scaling or tender fulfilment.

Ongoing net losses and negative EBIT

Continued negative EBIT and net losses weaken retained earnings and limit reinvestment capacity. Over time this can restrict product launches, marketing and international expansion, impair management's ability to pursue strategic partnerships, and increase vulnerability to competitive pressure.

Stagnant revenue and declining asset base

Stagnant top-line while total assets and equity decline suggests constrained growth capacity and erosion of scale. Structurally, this limits the firm's ability to invest in capacity, R&D or market development, reducing competitiveness and making recovery slower without strategic change.

Panacea Biotec Limited Business Overview & Revenue Model

Company Description

Panacea Biotec Limited, a biotechnology company, engages in the research and development, manufacture, and marketing of pharmaceuticals, vaccines, and biosimilars in India. It operates through Vaccines and Formulations segments. The company's product portfolio includes prescription products in various therapeutic areas, such as pain management, diabetes and cardiovascular management, oncology, renal disease management, osteoporosis management, anti-tubercular, and gastro-intestinal care; and vaccines for anthrax, dengue, Japanese encephalitis, and others. It also exports its products to over 30 countries worldwide, including the United States, Germany, the Russian Federation, Sri Lanka, the Philippines, etc. The company has a collaboration agreement with the Russian Direct Investment Fund for producing Covid-19 vaccine Sputnik-V; and the Coalition for Epidemic Preparedness Innovations and Translational Health Science and Technology Institute to develop vaccine candidates that could protect against SARS-Cov-2 variants and other Beta coronaviruses. Panacea Biotec Limited was incorporated in 1984 and is based in New Delhi, India.

How the Company Makes Money

Panacea Biotec makes money primarily by selling pharmaceutical products and vaccine/biologics-related products and services across domestic and international markets. Key revenue streams typically include: (1) Product sales of finished-dose pharmaceutical formulations (including branded and/or generic medicines) to hospitals, pharmacies, distributors, and institutional buyers; (2) Revenue from vaccines/biologics through sales to government procurement programs and private-market channels, where applicable; (3) Contract manufacturing and supply arrangements, where the company manufactures finished formulations or intermediates for other companies under agreed commercial terms; and (4) Potential licensing/technology transfer, milestone payments, or royalties from partnering its products, brands, or manufacturing capabilities with other pharmaceutical companies for co-marketing, distribution, or commercialization in specific territories. Significant earnings drivers generally include the scale of its manufacturing operations, product mix (higher-value specialty or vaccine products versus commoditized generics), participation in large institutional tenders (where applicable), export demand, pricing/competition dynamics, and regulatory approvals that enable market access. Specific named partnerships, product-level revenue contributions, and segment revenue splits are null.

Panacea Biotec Limited Financial Statement Overview

Summary

Financials show material strain: revenue is stagnant, EBIT and net income are negative, and operating/free cash flow are also negative. The main offset is a strong balance-sheet posture with very low leverage (debt-to-equity ~0.03) and a solid equity ratio (~64.73%), but declining assets/equity and weak cash generation keep the score low.

Income Statement

Panacea Biotec's income statement shows mixed performance with declining revenue and profitability. The gross profit margin for 2025 is approximately 64.31%, indicating decent cost management. However, the company has been experiencing negative EBIT and net income, reflecting operational challenges. The net profit margin is negative due to consistent net losses, and revenue growth has stagnated, showing no growth from 2024 to 2025.

Balance Sheet

The balance sheet indicates a strong equity position with a debt-to-equity ratio of 0.03 in 2025, showing effective leverage management. However, the company has faced declining total assets and stockholders' equity over the years. The equity ratio stands at 64.73% in 2025, suggesting a stable financial structure, but the decline in assets could be a concern for future growth.

Cash Flow

Panacea Biotec's cash flow statement reveals liquidity challenges, with negative operating cash flow and free cash flow in 2025. The company is struggling to generate cash from operations, reflected in the negative operating cash flow to net income ratio. The free cash flow to net income ratio is also negative, indicating a need for improvement in cash generation.

Breakdown	TTM	Mar 2025	Mar 2024	Mar 2023	Mar 2022	Mar 2021
Income Statement
Total Revenue	6.10B	5.59B	5.52B	4.57B	6.59B	6.18B
Gross Profit	3.75B	3.60B	446.53M	1.78B	3.42B	4.13B
EBITDA	540.00M	307.40M	415.37M	563.65M	16.74B	865.18M
Net Income	114.80M	-83.70M	-11.73M	-332.37M	10.78B	-1.48B
Balance Sheet
Total Assets	0.00	12.90B	12.41B	12.71B	17.59B	11.78B
Cash, Cash Equivalents and Short-Term Investments	1.10B	1.79B	1.56B	2.13B	5.52B	954.44M
Total Debt	0.00	222.10M	209.90M	202.19M	341.55M	8.20B
Total Liabilities	-8.31B	4.59B	4.02B	4.31B	8.85B	14.09B
Stockholders Equity	8.31B	8.35B	8.42B	8.44B	8.77B	-2.29B
Cash Flow
Free Cash Flow	0.00	-776.80M	-778.18M	-4.63B	-1.21B	850.01M
Operating Cash Flow	0.00	-273.70M	-1.00M	-4.22B	-1.08B	1.07B
Investing Cash Flow	0.00	649.80M	102.27M	4.30B	12.83B	-476.79M
Financing Cash Flow	0.00	-26.60M	-28.08M	-183.73M	-11.76B	-471.10M

Panacea Biotec Limited Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 358.50
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:PANACEABIO, the sentiment is Neutral. The current price of 358.5 is above the 20-day moving average (MA) of 341.96, below the 50-day MA of 365.48, and below the 200-day MA of 403.54, indicating a neutral trend. The MACD of -9.05 indicates Negative momentum. The RSI at 54.26 is Neutral, neither overbought nor oversold. The STOCH value of 63.10 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for IN:PANACEABIO.

Panacea Biotec Limited Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
AUROPHARMA	74 Outperform	₹746.82B	18.87	―	0.33%	7.33%	-3.79%
IPCALAB	74 Outperform	₹378.03B	27.58	―	0.28%	9.66%	25.79%
ALKEM	72 Outperform	₹671.84B	25.97	―	0.80%	9.32%	11.25%
GLAXO	63 Neutral	₹422.08B	35.44	―	2.16%	4.17%	41.51%
GLENMARK	53 Neutral	₹628.81B	35.61	―	0.24%	30.27%	―
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
PANACEABIO	51 Neutral	₹21.73B	144.78	―	―	9.78%	50.78%

Panacea Biotec Limited Corporate Events

Panacea Biotec Disputes ₹9.38 Crore Tax Penalty, Sees No Material Business Impact

Panacea Biotec Limited has disclosed that it has received three demand orders from the Office of the Assistant Commissioner of Income Tax, Central Circle 29, Delhi, imposing penalties totaling approximately ₹9.38 crore for alleged under-reporting of income for assessment years 2017-18, 2020-21 and 2021-22 under Section 270A of the Income Tax Act, 1961. The company maintains that the tax demand is not sustainable and plans to challenge the orders by filing an appeal with the appellate authority, adding that it does not expect any material impact on its financial position, operations or other activities, which may reassure investors and stakeholders about the limited immediate operational risk from this tax dispute.

Panacea Biotec Announces Leadership Changes and Policy Updates

Panacea Biotec Limited announced key changes in its leadership, with Mr. Vinod Goel appointed as the new Chief Financial Officer and Mr. Ankit Jain as the Company Secretary and Compliance Officer. These appointments, effective December 16, 2025, follow the resignation of the previous CFO, Mr. Devender Gupta. Additionally, the company has revised its policy for determining the materiality of events and authorized specific personnel for disclosures to stock exchanges, which may enhance its governance and operational transparency.